Rotterdam Science Tower, Marconistraat 16, 18th fl
21 articles with SkylineDx
SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to manage continuity of care delivery when resources are under pressure due to COVID.
BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206
- Agreement to characterize gene expression and immunological signature of tumors - SkylineDx focuses on discovery and development of novel gene-based biomarkers
It was another busy week for clinical trials. Here’s a look.
SkylineDx announced, during the European Society for Medical Oncology congress, that it successfully validated the performance of their skin cancer diagnostic test on the first, independent, European dataset.
SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester the launch of a pilot study it will conduct with the Mayo Clinic to evaluate and optimize its diagnostic services focused on primary cutaneous melanoma.
fast-progressing multiple myeloma patients of 65 years and older that won’t undergo a stem cell transplantation live 42 months longer when treated with the option of an MPR-R regime.
Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx’ market potential of over $1 billion annually based on their current progress in the melanoma field.
hematologists and multiple myeloma patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the diagnostic service provided by Everything Genetic Ltd. SkylineDx, the diagnostics company that developed the test, announced its collaboration with the UK based provider of a genetic testing service.
The Rotterdam headquartered diagnostics company has been granted CAP accreditation, following its CLIA certification in December 2018 and became the first Dutch scale-up with a CAP and CLIA certified clinical laboratory in San Diego, joining an elite group of globally recognized facilities that operate at the highest level of quality laboratory standards.
A substantial number of blood cancer patients could make more informed decisions on their treatment if more information becomes available for them and their treating physicians.
an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk patients) and show a favorable and distinct treatment strategy for the low and high-risk patients in an interim data analysis.
SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma
For SkylineDx, the collaboration with the renowned Mayo Clinic is an important milestone as it allows the company to develop new diagnostic tests and extend its product offering for a broader group of patients and clinicians.
SkylineDx's SKY92 Gene Signature Facilitates Cost-Effective, Risk-Stratified Treatment of Multiple Myeloma
This is the first study to examine the potential health economic value of RST in MM within the EU.
SkylineDx Researchers Publish Data Demonstrating Utility Of SKY92 As Prognostic Tool In Multiple Myeloma (MM)
Data Presentations At European Hematology Association 22nd Annual Congress Further Validate SkylineDx Prognostic Tools In Multiple Myeloma
SkylineDx Presented New Algorithm Demonstrating Ability To Successfully Identify Gene Sets That Are Informative Of Cancer Treatment Specific Survival
SkylineDx Announces Multiple Studies Being Presented At The 58th Annual American Society of Hematology Meeting Reinforcing Utility Of Mmprofiler Gene-Based Prognostic Signature To Impact Treatment Of Patients With Multiple Myeloma
SkylineDx And Consortium Of Leading European Partners Awarded Multi-Million Euro Horizon2020 Grant From European Commission (EC)